Terms: = Endocrine gland cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
16 results:
1. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
[TBL] [Abstract] [Full Text] [Related]
2. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma.
Herremans KM; Szymkiewicz DD; Riner AN; Bohan RP; Tushoski GW; Davidson AM; Lou X; Leong MC; Dean BD; Gerber M; Underwood PW; Han S; Hughes SJ
Neoplasia; 2022 Jun; 28():100789. PubMed ID: 35395492
[TBL] [Abstract] [Full Text] [Related]
3. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract] [Full Text] [Related]
4. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
[TBL] [Abstract] [Full Text] [Related]
5. cancer testis antigen Cyclin A1 harbors several hla-a*02:01-restricted T cell epitopes, which are presented and recognized in vivo.
Teck AT; Urban S; Quass P; Nelde A; Schuster H; Letsch A; Busse A; Walz JS; Keilholz U; Ochsenreither S
Cancer Immunol Immunother; 2020 Jul; 69(7):1217-1227. PubMed ID: 32157447
[TBL] [Abstract] [Full Text] [Related]
6. HLA Class I Expression Changes in Different Types of Cultured Parathyroid Cells.
Goncu B; Yucesan E; Aysan E; Kandas NO
Exp Clin Transplant; 2022 Sep; 20(9):854-862. PubMed ID: 30995898
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Characteristics and Postoperative Recovery of Hypopituitarism in Patients with Nonfunctional Pituitary Adenoma.
Zhang R; Wang Z; Gao L; Guo X; Feng C; Deng K; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
World Neurosurg; 2019 Jun; 126():e1183-e1189. PubMed ID: 30880207
[TBL] [Abstract] [Full Text] [Related]
8. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
[TBL] [Abstract] [Full Text] [Related]
9. HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas.
Rutten MJ; Dijk F; Savci-Heijink CD; Buist MR; Kenter GG; van de Vijver MJ; Jordanova ES
J Immunol Res; 2014; 2014():274584. PubMed ID: 24987709
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of secondary and primary thyroid cancer in adolescents and young adults.
Goldfarb M; Freyer DR
Cancer; 2014 Apr; 120(8):1155-61. PubMed ID: 24615715
[TBL] [Abstract] [Full Text] [Related]
11. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S; Koido S; Takeda Y; Homma S; Komita H; Takahara A; Morita S; Ito T; Morimoto S; Hara K; Tsuboi A; Oka Y; Yanagisawa S; Toyama Y; Ikegami M; Kitagawa T; Eguchi H; Wada H; Nagano H; Nakata J; Nakae Y; Hosen N; Oji Y; Tanaka T; Kawase I; Kumanogoh A; Sakamoto J; Doki Y; Mori M; Ohkusa T; Tajiri H; Sugiyama H
J Immunother; 2014; 37(2):105-14. PubMed ID: 24509173
[TBL] [Abstract] [Full Text] [Related]
12. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
[TBL] [Abstract] [Full Text] [Related]
13. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
Diefenbach CS; Gnjatic S; Sabbatini P; Aghajanian C; Hensley ML; Spriggs DR; Iasonos A; Lee H; Dupont B; Pezzulli S; Jungbluth AA; Old LJ; Dupont J
Clin Cancer Res; 2008 May; 14(9):2740-8. PubMed ID: 18451240
[TBL] [Abstract] [Full Text] [Related]
14. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract] [Full Text] [Related]
15. Distant metastases in ovarian carcinoma.
Cormio G; Rossi C; Cazzolla A; Resta L; Loverro G; Greco P; Selvaggi L
Int J Gynecol Cancer; 2003; 13(2):125-9. PubMed ID: 12657111
[TBL] [Abstract] [Full Text] [Related]
16. Identification of hla-a*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2.
Konopitzky R; König U; Meyer RG; Sommergruber W; Wölfel T; Schweighoffer T
J Immunol; 2002 Jul; 169(1):540-7. PubMed ID: 12077286
[TBL] [Abstract] [Full Text] [Related]
